Skip to main content
. Author manuscript; available in PMC: 2017 Nov 15.
Published in final edited form as: Immunity. 2016 Oct 25;45(5):1052–1065. doi: 10.1016/j.immuni.2016.10.005

Figure 2. cDCs are not Required Constitutively for the AM14 Response.

Figure 2

(A) Experiment design. 4 × 106 AM14.MRL.Faslpr B cells were transferred into MRL.Faslpr recipients that were either double positive for both the CD11c-cre and Rosa26-flox-stop-DTA Tgs, and thus lacked cDCs (ΔDC mice), or into single Tg positive littermates (Cntrl) on day 0. The AM14 B cell response was activated with PL2-3 on days 0, 2 and 4, or left untreated (no Ag). As additional controls, some mice did not receive cell transfer or Ag (no Tfr). Spleens were harvested on day 6.

(B) Number of AM14 B cells (4-44+) per spleen.

(C) Number of AM14 plasmablasts (4-44+, CD22lo, CD44hi) per spleen.

(D, E, & F) ELISpot assays for the number of 4-44+, IgM+, IgG2a+, or IgG2b+ AFCs per spleen. Data were combined from 3 experiments to obtain 12-24 mice per group receiving PL2-3 and 2-12 mice in the untreated groups. Bars represent mean and SEM. See also Figure S3.